



Remicade Patient Referral Form

Patient Name: _____ Date: _____

SSN#: _____ DOB: _____ Primary Phone: _____ Work Phone: _____

Address: _____ City: _____ State: _____ Zip: _____

Primary Diagnosis: Please fill in appropriate ICD-10 code, see reverse side for all ICD-10 codes
Rheumatoid Arthritis, Ulcerative colitis, Ankylosing Spondylitis, Psoriasis, Psoriatic arthritis mutilans, Crohn's disease, Other ICD-10

1 Patient Information: In order to service your patient and facilitate insurance authorization, please complete the following.

Attach documents to FAX (see below)

NKDA Allergies: _____
Ht: _____ in/cm Wt: _____ lbs/kg Male Female
Is this the first Remicade infusion: Yes No
Date of last infusion: _____ Next dose due: _____
Line type: PIV PICC Port Other: _____ Lumen #: _____

Copy of insurance card
Patient demographics
Labs
H&P
Immunization results, include HBV and TB
Other: _____

2 Clinical Information: ARJ policies and protocols to be provided upon request.

Initial Dosing, Maintenance Dosing, Directions, Quantity/Refills
Remicade 3 mg/kg IV at week 0, 2, and 6
Remicade 5 mg/kg IV at week 0, 2 and 6
Infuse per manufacturer guidelines OR over _____ hours (may not be less than 2 hours.)
Dispense: 1 month supply on all selected medications
Refill x12 months unless otherwise noted
RN to start peripheral IV or use existing CVC. RN to administer catheter flushing per ARJ Policy and Procedure
Give premedication 30 minutes prior to infusion
Diphenhydramine: 25-50 mg po OR 50 mg IV diluted in D5W or NS 50-100mL, infuse over 10-15 mins.
Antihistamine: Fexofenadine 180 mg po OR Cetirizine 10 mg po
Methylprednisolone: 125 mg slow IV push over 5 mins. OR _____ mg slow IV push over 5 mins.
Acetaminophen: 325-650 mg po OR _____ mg po
D5W or NS 500mL - 1L IV over 30 minutes - 1 hour as tolerated daily PRN for hydration and/or headache
RN to monitor patient for minimum of 30 minutes post infusion. RN to educate patient on possible side effects, allergic reactions, and when to contact physician.
RN to instruct patient to hydrate pre/post infusion. RN to instruct patient to take Diphenhydramine 25-50 mg po and Acetaminophen 325-650 mg po every 4-6 hours for 24-48 hours as needed to prevent/treat post infusion headache.
Adverse Reaction Orders: (Dispense 1 dose of each medication below)
In the event of an infusion reaction (ie: fever, chills, backache, headache) the following orders will be followed and physician will be notified.
Note: For mild reactions, patient may be treated, and infusion resumed at a slower rate.
STOP infusion. Infuse D5W or NS at 20 mL/hr to keep line open, may increase to 100-250 mL/hr for hydration. May give the following if stopping infusion does not resolve symptoms:
Diphenhydramine 50 mg IV diluted in D5W or NS 50-100 mL, infused over 10-15 minutes or 50 mg/10 mL NS IV push over 2-3 minutes, as tolerated.
Methylprednisolone 125 mg (OR _____ mg) slow IV push over 5 minutes.
Acetaminophen 325-650 mg (OR _____ mg) po at onset of symptoms.
Ondansetron 4 mg slow IV push over 5 minutes or 4 mg ODT.
Epinephrine pen by weight for use IM or SQ in anaphylactic reaction. May repeat one time. EMS/911 will be called if used.

3 Prescriber Information: By signing I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment. ARJ Infusion Services has my permission to contact the patient's health plan to obtain any authorizations necessary to enable it to receive payment for services.

Physician Name: _____ Office Contact: _____
Address: _____ City: _____
State: _____ Zip: _____ Phone: _____ Fax: _____
License #: _____ DEA#: _____ NPI #: _____
Date: _____ Date: _____

Physician Signature Required - Substitution Permitted

Physician Signature Required - Dispense as Written

Confidential Health Information: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization and under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state law. Important Warning: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any discrimination, distribution, or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.

Rheumatoid Arthritis

- M05.40** Rheumatoid myopathy with rheumatoid arthritis of unspecified site
- M06.9** Rheumatoid Arthritis, unspecified

Psoriatic arthritis mutilans

- L40.52** Psoriatic arthritis mutilans

Ulcerative colitis

- K51.919** Ulcerative colitis, unspecified with unspecified complications

Crohn's disease

- K50.819** Crohn's disease of both small and large intestine with unspecified complications
- K50.80** Crohn's disease of both small and large intestine without complications
- K50.019** Crohn's disease of small intestine with unspecified complications
- K50.919** Crohn's disease, unspecified, with unspecified complications
- K50.90** Crohn's disease, unspecified, without complications
- K50.10** Crohn's disease of large intestine without complications

Ankylosing Spondylitis

- M45.9** Ankylosing spondylitis of unspecified sites in spine

Psoriasis

- L40.0** Psoriasis vulgaris
- L40.9** Psoriasis, unspecified

Other: _____

